Peringatan Keamanan

As a mouse/rat hybrid antibody, Catumaxomab can produce immunogenicity in other species A31531. No acute toxicity was found in mice using an analog with an anti-mouse CD3 paratope in place of Catumaxomab's anti-human CD3 paratope. A transient decrease in serum leukocytes has been observed but is attributed to migration of immune cells into EpCAM positive tissues. Data specific to Catumaxomab is extremely limited as its specificity for human protein requires data from human subjects FDA Label.

Catumaxomab

DB06607

biotech approved investigational withdrawn

Deskripsi

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites L1122. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition FDA Label. It is currently available under the brand name Removab.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Catumaxomab has an observed bioavailability of 82% A31533. This value decreases as the EpCAM positive tumour load and number of immune cells in the peritoneal cavity increases. While some Catumaxomab escapes into systemic circulation, most localizes to EpCAM positive tissues. Tmax is 19 h.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Catumaxomab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Catumaxomab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Catumaxomab.
Estrone Estrone may increase the thrombogenic activities of Catumaxomab.
Estradiol Estradiol may increase the thrombogenic activities of Catumaxomab.
Dienestrol Dienestrol may increase the thrombogenic activities of Catumaxomab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Catumaxomab.
Mestranol Mestranol may increase the thrombogenic activities of Catumaxomab.
Estriol Estriol may increase the thrombogenic activities of Catumaxomab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Catumaxomab.
Quinestrol Quinestrol may increase the thrombogenic activities of Catumaxomab.
Hexestrol Hexestrol may increase the thrombogenic activities of Catumaxomab.
Tibolone Tibolone may increase the thrombogenic activities of Catumaxomab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Catumaxomab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Catumaxomab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Catumaxomab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Catumaxomab.
Zeranol Zeranol may increase the thrombogenic activities of Catumaxomab.
Equol Equol may increase the thrombogenic activities of Catumaxomab.
Promestriene Promestriene may increase the thrombogenic activities of Catumaxomab.
Methallenestril Methallenestril may increase the thrombogenic activities of Catumaxomab.
Epimestrol Epimestrol may increase the thrombogenic activities of Catumaxomab.
Moxestrol Moxestrol may increase the thrombogenic activities of Catumaxomab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Catumaxomab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Catumaxomab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Catumaxomab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Catumaxomab.
Biochanin A Biochanin A may increase the thrombogenic activities of Catumaxomab.
Formononetin Formononetin may increase the thrombogenic activities of Catumaxomab.
Estetrol Estetrol may increase the thrombogenic activities of Catumaxomab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Catumaxomab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Catumaxomab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Catumaxomab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Catumaxomab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Catumaxomab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Catumaxomab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Catumaxomab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Catumaxomab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Catumaxomab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Catumaxomab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Catumaxomab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Catumaxomab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Catumaxomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Catumaxomab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Catumaxomab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Catumaxomab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Catumaxomab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Catumaxomab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Catumaxomab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Catumaxomab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Catumaxomab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Catumaxomab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Catumaxomab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Catumaxomab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Catumaxomab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Catumaxomab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Catumaxomab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Catumaxomab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Catumaxomab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Catumaxomab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Catumaxomab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Catumaxomab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Catumaxomab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Catumaxomab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Catumaxomab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Catumaxomab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Catumaxomab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Catumaxomab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Catumaxomab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Catumaxomab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Catumaxomab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Catumaxomab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Catumaxomab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Catumaxomab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Catumaxomab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Catumaxomab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Catumaxomab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Catumaxomab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Catumaxomab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Catumaxomab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Catumaxomab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Catumaxomab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Catumaxomab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Catumaxomab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Catumaxomab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Catumaxomab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Catumaxomab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Catumaxomab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Catumaxomab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Catumaxomab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Catumaxomab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Catumaxomab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Catumaxomab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Catumaxomab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Catumaxomab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Catumaxomab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Catumaxomab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Catumaxomab.

Target Protein

Low affinity immunoglobulin gamma Fc region receptor II-a FCGR2A
Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A
Low affinity immunoglobulin gamma Fc region receptor III-B FCGR3B
T-cell surface glycoprotein CD3 epsilon chain CD3E
High affinity immunoglobulin gamma Fc receptor I FCGR1A
Epithelial cell adhesion molecule EPCAM

Referensi & Sumber

Synthesis reference: Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36(6):458-67. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995;155(1):219-25.
Artikel (PubMed)
  • PMID: 20347527
    Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27.
  • PMID: 20565453
    Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H: Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010 Jun;69(6):617-25. doi: 10.1111/j.1365-2125.2010.03635.x.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Removab
    Solution • 0.1 mg / mL • Intraperitoneal • Canada • Approved
  • Removab
    Solution • 0.1 mg / mL • Intraperitoneal • Canada • Approved
  • Removab
    Injection, solution, concentrate • 10 microgram • Intraperitoneal • EU
  • Removab
    Injection, solution, concentrate • 50 microgram • Intraperitoneal • EU

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul